Idiopathic eosinophilic myositis

Summary

Idiopathic eosinophilic myositis (MONDO:0016610) is a disease. A subtype of acquired idiopathic inflammatory myopathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	idiopathic eosinophilic myositis
Mondo ID	MONDO:0016610
Orphanet	247724
UMLS	C4755301
MedGen	1659844
GARD	0020664
Is cancer (heuristic)	no

Also known as: idiopathic eosinophilia-associated myopathy

Disease family

This is a subtype of acquired idiopathic inflammatory myopathy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › muscle tissue disorder › skeletal muscle disorder › acquired skeletal muscle disease › acquired idiopathic inflammatory myopathy › idiopathic eosinophilic myositis

Related subtypes (8): eosinophilic fasciitis, immune-mediated necrotizing myopathy, overlap myositis, inflammatory myopathy with abundant macrophages, juvenile idiopathic inflammatory myopathy, focal myositis, polymyositis, antisynthetase syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.